ArticleJournal of the Korean Society of Radiology2026
Utility of Tumor Sphericity on CT for Differentiating Fat-Poor Angiomyolipoma from Renal Cell Carcinoma.
Article in Journal of the Korean Society of Radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the utility of tumor sphericity on CT as a quantitative shape parameter for distinguishing fat-poor angiomyolipoma (AML) from renal cell carcinoma (RCC) in small renal masses (SRMs, maximum diameter ≤4 cm). Materials and Methods: We retrospectively evaluated 238 solitary sporadic SRMs that were pathologically confirmed as either AML or RCC and showed no visible fat on unenhanced CT. Tumor volume and sphericity were obtained through volumetric analysis using dedicated software. To distinguish fat-poor AML from RCC, clinical and imaging findings were compared, and receiver operating characteristic (ROC) curve analysis was performed. Binary logistic regression analysis was conducted to identify variables independently associated with fat-poor AML. Results: Among the 238 SRMs, 22 were diagnosed as AMLs and 216 as RCCs, comprising 173 clear cell, 25 papillary, and 18 chromophobe subtypes. Fat-poor AMLs were significantly more prevalent in female and had lower tumor volumes than RCCs (both Conclusion: Tumor sphericity serves as a quantitative shape parameter for distinguishing fat-poor AML from RCC in SRMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.